Scaffolds and the scaffolding domain: an alternative paradigm for caveolin-1 signaling.

caveolae caveolins endothelial nitric oxide synthase scaffolding domain signaling

Journal

Biochemical Society transactions
ISSN: 1470-8752
Titre abrégé: Biochem Soc Trans
Pays: England
ID NLM: 7506897

Informations de publication

Date de publication:
25 Mar 2024
Historique:
received: 21 12 2023
revised: 10 03 2024
accepted: 11 03 2024
medline: 25 3 2024
pubmed: 25 3 2024
entrez: 25 3 2024
Statut: aheadofprint

Résumé

Caveolin-1 (Cav1) is a 22 kDa intracellular protein that is the main protein constituent of bulb-shaped membrane invaginations known as caveolae. Cav1 can be also found in functional non-caveolar structures at the plasma membrane called scaffolds. Scaffolds were originally described as SDS-resistant oligomers composed of 10-15 Cav1 monomers observable as 8S complexes by sucrose velocity gradient centrifugation. Recently, cryoelectron microscopy (cryoEM) and super-resolution microscopy have shown that 8S complexes are interlocking structures composed of 11 Cav1 monomers each, which further assemble modularly to form higher-order scaffolds and caveolae. In addition, Cav1 can act as a critical signaling regulator capable of direct interactions with multiple client proteins, in particular, the endothelial nitric oxide (NO) synthase (eNOS), a role believed by many to be attributable to the highly conserved and versatile scaffolding domain (CSD). However, as the CSD is a hydrophobic domain located by cryoEM to the periphery of the 8S complex, it is predicted to be enmeshed in membrane lipids. This has led some to challenge its ability to interact directly with client proteins and argue that it impacts signaling only indirectly via local alteration of membrane lipids. Here, based on recent advances in our understanding of higher-order Cav1 structure formation, we discuss how the Cav1 CSD may function through both lipid and protein interaction and propose an alternate view in which structural modifications to Cav1 oligomers may impact exposure of the CSD to cytoplasmic client proteins, such as eNOS.

Identifiants

pubmed: 38526159
pii: 234224
doi: 10.1042/BST20231570
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CIHR
ID : PJT-175112
Pays : Canada

Informations de copyright

© 2024 The Author(s).

Auteurs

John E Lim (JE)

Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia (UBC), 2176 Health Sciences Mall, Room 217, Vancouver, BC V6T 1Z3, Canada.

Pascal Bernatchez (P)

Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia (UBC), 2176 Health Sciences Mall, Room 217, Vancouver, BC V6T 1Z3, Canada.
Centre for Heart and Lung Innovation, St. Paul's Hospital, Vancouver, Canada.

Ivan R Nabi (IR)

Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
School of Biomedical Engineering, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

Classifications MeSH